PropThink: ACHN Keeps Advancing, Visibility As Leader In Next-Gen HCV Drugs Increases

[ACN Newswire] – By David MoskowitzAchillion Pharmaceuticals (NASDAQ:ACHN) is up nearly 80% since its summer lows (see our initial article here ), as the hepatitis C (HCV) space continues to evolve. While Gilead’s (NASDAQ:GILD) … more

View todays social media effects on ACHN

View the latest stocks trending across Twitter. Click to view dashboard